These innovative agents represent a significant progression in the therapy of type 2 diabetes. Retatrutide, a dual GLP-1 and GIP receptor agonist, demonstrates exceptional efficacy in lowering blood glucose levels. https://jasoniimc439750.thekatyblog.com/37444195/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide